Formulation and in vitro evaluation of crisaborole-loaded solid lipid nanoparticles - topical system for atopic dermatitis

Background: Designing and testing a new way to deliver drugs through the skin using Solid Lipid Nanoparticles (SLNs) for sustained as well as enhanced topical delivery of Crisaborole. Methodology: Crisaborole was incorporated into SLNs using the Double Emulsification Solvent Evaporation Method. The SLNs were enhanced using a Box-Behnken design. The best-performing formulation was evaluated after optimization for particle size, etc, along with entrapment efficiency and in vitro release. Results: The SLNs exhibited a remarkable entrapment efficacy of 69.8 ± 1.1% to 80.6 ± 0.3%, and their particle size varied from 222.1 ± 8.5 nm to 440 ± 7.5 nm. In the in vitro release study of Crisaborole-SLNs, 92.7 ± 1.17 % was observed at 12 hours. The developed SLN formulation displays no significant change after three months of stability study under accelerated conditions. Conclusion: These results suggest that crisaborole-loaded solid lipid nanoparticles (SLNs) represent a promising vehicle for the topical delivery of crisaborole, with potential for enhanced dermal residence due to controlled release and nanoscale size within the skin, while minimizing systemic exposure.